KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial. PMID 41310935 · BJU Int · 2026-Mar Eligibility requires a definitive Phase II/III or Phase III randomized trial with a drug-containing intervention and a primary or key secondary time-to-event efficacy endpoint. This study is randomized and oncology-related but lacks explicit Phase III status, does not involve a systemic drug intervention (it tests nutritional support), and does not report any time-to-event endpoints (OS, PFS, DFS, etc.) or survival analyses (Kaplan-Meier, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. PMID 41296193 · Oncol Ther · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow-up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. PMID 41293883 · Histopathology · 2026-Mar The study is an oncology randomized trial with a time-to-event endpoint, but it lacks a drug intervention (it's a screening study) and the trial phase is not specified as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. PMID 41276768 · Ann Surg Oncol · 2026-Mar While the trial is randomized, oncologic, human, includes a drug intervention, and reports time-to-event efficacy endpoints, the abstract and metadata do not explicitly state the trial phase (e.g., Phase II or Phase III). The inclusion criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not present. Therefore, the record is ineligible due to missing phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population. PMID 41223063 · Urol Pract · 2026-Mar The record describes a randomized trial of a decision aid for prostate cancer screening decision-making. While it is oncology-related and human, it lacks a drug-containing intervention (the intervention is a decision aid, not a pharmaceutical) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recovery After Transcervical Fibroid Ablation Versus Minimally Invasive Myomectomy for Symptomatic Uterine Fibroids: A Randomised Controlled Trial. PMID 41208417 · BJOG · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of multidisciplinary ERAS-based nursing model on postoperative recovery in patients undergoing radical resection for oral cancer. PMID 41207560 · J Stomatol Oral Maxillofac Surg · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial. PMID 41176433 · Eur Urol · 2026-Mar The record is a letter/commentary ('Re:') with no abstract or full text. While the title mentions a randomized Phase 3 trial with a drug intervention, the absence of the original trial report means key eligibility criteria (human, original_result, time_to_event) cannot be established. The title alone is insufficient to confirm a formal result report with a primary/key secondary time-to-event endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma. PMID 41137728 · Head Neck · 2026-Mar The study is a retrospective review comparing neoadjuvant immunotherapy to upfront surgery, not a randomized controlled trial. The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the abstract describes a retrospective matched cohort design, not a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma. PMID 41087785 · Ann Surg Oncol · 2026-Mar This is a survey of expert opinion and practice patterns, not a report of original results from a randomized controlled trial. It does not present time-to-event efficacy data.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Artificial Intelligence 3D Augmented Reality-guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial. PMID 41087293 · Eur Urol · 2026-Mar The study is a randomized oncology trial with original results, but it does not meet two key inclusion criteria: 1) The intervention is not a drug (it compares surgical guidance technologies), and 2) The primary efficacy endpoint is not a time-to-event endpoint (e.g., OS, PFS, DFS) or a time-to-event analysis (e.g., Kaplan-Meier, HR); the primary endpoint was positive surgical margin (PSM) rate, a pathological outcome. While biochemical recurrence (BCR) is mentioned, it is not reported as a time-to-event analysis with Kaplan-Meier curves or hazard ratios in the provided abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 2025;88:510-518. PMID 41073257 · Eur Urol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study. PMID 41004307 · Clin Exp Rheumatol · 2026-Mar The study is a subanalysis of a randomized trial in rheumatoid arthritis, not an oncology trial. The primary endpoint is a radiographic damage score (mTSS), not a time-to-event endpoint such as OS, PFS, DFS, etc. There is no evidence of Kaplan-Meier analysis or hazard ratios for time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in cancer patients: A randomized controlled trial. PMID 40785239 · J Health Psychol · 2026-Mar The study meets criteria for being an oncology, human, randomized, original-result report, but is excluded because the intervention is non-drug and the primary endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. PMID 40738276 · Clin Gastroenterol Hepatol · 2026-Mar The record describes a Phase 3 randomized trial of upadacitinib for Crohn's disease, which is not an oncologic malignancy. The primary endpoints (CDAI clinical remission and endoscopic response at week 52) are categorical outcomes at a fixed time, not time-to-event endpoints such as OS, PFS, DFS, or time-to-event analyses (e.g., Kaplan-Meier curves, hazard ratios for time to event). Therefore, it does not meet the cohort's inclusion criteria for an oncology trial with a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study. PMID 40721359 · J Health Psychol · 2026-Mar The record describes a randomized trial of non-drug interventions (cognitive behavioral therapy vs. health management content) for fear of cancer recurrence in breast cancer survivors. While it is an oncology human randomized trial with original results, it is ineligible because it lacks a Phase III designation, lacks a time-to-event efficacy endpoint (e.g., OS, PFS), and lacks a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Lumen-Apposing Stents With or Without Pigtail in Endosonography-Guided Biliary Drainage for Malignant Distal Biliary Obstruction. PMID 40701486 · Clin Gastroenterol Hepatol · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Enhancing the Quality of Hospice Shared Care for End-Stage Malignant Tumor Patients: A Structure-process-outcome Three-Dimensional Quality Evaluation Model. PMID 40403769 · Am J Hosp Palliat Care · 2026-Mar The study is an oncology randomized controlled trial with original results, but it does not meet the key eligibility criteria: 1) The endpoint is quality of life, spiritual well-being, psychological distress, and patient satisfaction, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). 2) The intervention is a hospice care model, not a drug-containing intervention. 3) The phase is not specified as Phase III or a definitive Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial. PMID 40319177 · Prostate Cancer Prostatic Dis · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. PMID 40140551 · Prostate Cancer Prostatic Dis · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of reinforced pancreaticojejunostomy with or without tissue adhesive glue modified cyanoacrylate following pancreaticoduodenectomy: a randomized controlled clinical trial. PMID 42381068 · World J Surg Oncol · 2026-Jun-30 The record is an oncology randomized controlled trial in humans with original primary results, but it is excluded because the phase is not established as definitive (Phase III/IIIb or Phase II/III), the intervention is a surgical technique/adjunct (tissue adhesive) rather than a systemic drug therapy, and the primary efficacy endpoint is a surgical complication rate (POPF), not a time-to-event endpoint like OS, PFS, DFS, etc.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A). PMID 42380720 · Esophagus · 2026-Jun-30 This is an ancillary/subgroup analysis of a Phase III trial (JCOG1109) that evaluates inter-institutional heterogeneity. While it references the parent trial's design and includes survival data, it is not the primary or final report of the randomized trial's efficacy results. It analyzes variance in outcomes across institutions, which constitutes a secondary/heterogeneity analysis. The explicit evidence for randomization in the parent trial is mentioned (it's a Phase III multicenter trial comparing three arms), but this specific record is not the original result report of that trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparison of the Effects of Intraoperative Pectoral Nerve Block and Local Wound Infiltration in Pain Management for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 42376719 · J Perianesth Nurs · 2026-Jun-29 The study is a randomized trial in oncology patients, but it evaluates a local anesthetic technique for postoperative pain, not a drug intervention with a cancer-related time-to-event efficacy endpoint. It is excluded due to lack of qualifying drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants. PMID 42371393 · Eur J Drug Metab Pharmacokinet · 2026-Jun-29 The study is a Phase 1, randomized, open-label, crossover pharmacokinetic/bioequivalence study in healthy adults. Although it involves an oncology drug (vepdegestrant) for a cancer indication, the trial is Phase I, the primary endpoints are pharmacokinetic (AUC, Cmax), and it does not assess time-to-event efficacy outcomes (e.g., OS, PFS, DFS, HR, Kaplan-Meier) in cancer patients. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort of definitive efficacy trials.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01). PMID 42370451 · J Hepatobiliary Pancreat Sci · 2026-Jun-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial. PMID 42364816 · Radiother Oncol · 2026-Jun-27 干预为非药物单独策略,未满足药物干预要求。
H B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. PMID 42363777 · Int J Cancer · 2026-Jun-27 The record does not meet all eligibility criteria: while it is an oncology-related, human, randomized trial with a time-to-event endpoint and original results, it lacks a drug-containing intervention and explicit Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. PMID 42361276 · J Clin Oncol · 2026-Jun-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. PMID 42360803 · Clin Cancer Res · 2026-Jun-26 This is a pre-specified biomarker subgroup analysis of the ENZAMET trial, not the primary result report of the randomized Phase III trial itself. The primary trial results are reported elsewhere.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study. PMID 42360473 · J Neurol · 2026-Jun-26 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-led, home-based follow-up for colorectal cancer: the DISTANCE multicentre stepped-wedge cluster-randomised trial. PMID 42359543 · Br J Surg · 2026-Jun-26 The record is an oncology, human, randomized trial with results, but it is excluded because it is not a Phase III/IIIb or definitive Phase II/III trial, does not contain a drug-containing intervention (it is a non-drug follow-up model comparison), and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint was hospital contacts, and secondary endpoints included QoL and distress metrics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning. PMID 42348666 · Curr Opin Hematol · 2026-Jun-26 The record is a journal article review article (publication_type: Journal Article) summarizing mechanistic and clinical data on factor XIa inhibitors. It is not an original result report of a Phase III/IIIb or Phase II/III randomized trial. The review mentions oncology (cancer-associated thrombosis) as a potential indication, but does not report results of an oncology trial with a time-to-event efficacy endpoint. It does not contain original Kaplan-Meier data, HR, or other time-to-event results for an oncology indication.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. PMID 42360727 · JNCI Cancer Spectr · 2026-Jun-25 The record describes a secondary/prognostic biomarker analysis within a large randomized trial (MA.32). While the trial itself may be a definitive Phase III study, the specific report provided does not explicitly state the trial phase, and its primary focus is not on evaluating a drug intervention's efficacy but on the prognostic value of CA 15-3. Therefore, it fails the 'drug intervention' and 'explicit phase' criteria for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Strengthening cancer prevention in european schools: a randomized controlled trial of digital interventions in adolescents: the SUNRISE program. PMID 42351094 · BMC Public Health · 2026-Jun-25 The record describes a protocol for a cluster-randomized controlled trial of a digital health intervention for cancer prevention in adolescents. It is not a report of a completed Phase II/III or Phase III/IIIb randomized trial in human malignant neoplasm patients with a drug intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicenter randomized controlled trial comparing metallic stents with 10- versus 14-mm diameter for distal biliary obstruction caused by unresectable pancreatic carcinoma. PMID 42349763 · Gastrointest Endosc · 2026-Jun-25 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. PMID 42347868 · Clin Cancer Res · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. PMID 42341302 · N Engl J Med · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. PMID 41999744 · Cell · 2026-Jun-25 The record describes a secondary, exploratory biomarker analysis (gut microbiome and recurrence) from a Phase III randomized trial (CheckMate 915). While it reports on recurrence-free survival (a time-to-event endpoint) in a drug-intervention trial, it is not the primary or key secondary efficacy report of the original trial's results. The analysis is a subgroup/post-hoc biomarker study, not the formal report of the trial's primary or pre-specified secondary efficacy outcomes (e.g., overall survival or the primary comparison of nivolumab+ipilimumab vs nivolumab for recurrence-free survival). Therefore, it is excluded as not being an original formal-result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improving basal cell carcinoma subtype diagnosis with dermoscopy and reflectance confocal microscopy: a multicentre prospective study. PMID 41685950 · Clin Exp Dermatol · 2026-Jun-25 The record describes a prospective diagnostic accuracy study for noninvasive imaging of basal cell carcinoma subtypes, not a randomized drug trial. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and is not a Phase III or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. PMID 42396282 · medRxiv · 2026-Jun-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PMID 42343117 · Nat Med · 2026-Jun-24 The record is a retraction notice for a previously published trial. The abstract is empty, so no details about the study population (human), intervention (drug), or primary/time-to-event endpoints can be verified. Therefore, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment. PMID 42431149 · Clin Breast Cancer · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical translation of an immunomodulatory cell therapy that is designed to convert "cold" tumors to "hot": A phase 2B trial in 3L MSS/pMMR metastatic colorectal cancer. PMID 42335577 · Transl Oncol · 2026-Jun-23 The trial is a Phase 2B, single-arm study. It is not randomized and is not Phase III/IIIb or Phase II/III, which are required eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. PMID 41949390 · Blood Adv · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Efficacy of Modified San'ao Decoction and Erchen Decoction for Esophageal Dysphagia (Shi Bi) with Phlegm-Dampness and Blood Stasis Syndrome. PMID 42406624 · J Vis Exp · 2026-Jun-22 The record is a protocol for a randomized controlled trial with drug interventions (camrelizumab, anlotinib) in oncology. However, it is a protocol without final, peer-reviewed results reporting primary/key secondary time-to-event endpoints (OS, PFS, etc.). The abstract describes preliminary, short-term efficacy (ORR, DCR) and safety findings, but not Kaplan-Meier, HR, or other time-to-event data. The phase is not explicitly stated as Phase III/IIIb; the design is open-label and single-center, limiting definitiveness. Therefore, it does not meet all criteria for inclusion as a definitive Phase III RCT with time-to-event results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Integration of lung tissue proteomics and genome-wide association data to identify lung cancer susceptibility proteins and potential drug targets. PMID 42396338 · medRxiv · 2026-Jun-22 The record describes a genomic/proteomic study identifying lung cancer susceptibility proteins and potential drug targets. It is not a clinical trial report and lacks the core elements of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Parathyroid Hormone Modifies the Effect of Vitamin D Supplementation on Risk of Relapse or Death in Patients with Digestive Tract Cancer: A Post Hoc Subgroup Analysis of the AMATERASU Randomized Clinical Trial. PMID 42352547 · Cancers (Basel) · 2026-Jun-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. PMID 42323161 · Ann Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium. PMID 42321916 · Trials · 2026-Jun-20 The record describes the design of a complex clinical trial (CHIP-AML22) but is a protocol paper, not an original report of formal results. While it includes randomized comparisons and time-to-event endpoints, the Phase III status is not explicitly confirmed in the provided metadata, and the report type is 'protocol' which is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). PMID 42096662 · J Clin Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -